Literature DB >> 27592808

Ablation of the basivertebral nerve for treatment of back pain: a clinical study.

Stephan Becker1, Alexander Hadjipavlou2, Michael H Heggeness3.   

Abstract

BACKGROUND CONTENT: Lumbar axial back pain arising from degenerative disc disease continues to be a challenging clinical problem whether treated with nonsurgical management, local injection, or motion segment stabilization and fusion.
PURPOSE: The purpose of this study was to determine the efficacy of intraosseous basivertebral nerve (BVN) ablation for the treatment of chronic lumbar back pain in a clinical setting. STUDY
DESIGN: Patients meeting predefined inclusion or exclusion criteria were enrolled in a study using radiofrequency energy to ablate the BVN within the vertebral bodies adjacent to the diagnosed level. Patients were evaluated at 6 weeks, and 3, 6, and 12 months postoperatively. PATIENT SAMPLE: Seventeen patients with chronic, greater than 6 months, low back pain unresponsive to at least 3 months of conservative care were enrolled. Sixteen patients were treated successfully following screening using magnetic resonance imaging finding of Modic type I or II changes and positive confirmatory discography to determine the affected levels. The treated population consisted of eight male and eight female patients; the mean age was 48 years (34-66 years). OUTCOME MEASURES: Self-reported outcome measures were collected prospectively at each follow-up interval. Measures included the Oswestry Disability Index (ODI), visual analogue scale score, and Medical Outcomes Trust 36-Item Short-Form Health Survey (SF-36).
MATERIALS AND METHODS: This is an industry-sponsored study to evaluate the effectiveness of intraosseous nerves in the treatment of chronic back pain. Consented and enrolled patients underwent ablation of the BVN using radiofrequency energy (INTRACEPT System, Relievant Medsystems, Inc, Redwood City, CA, USA) guided in a transpedicular or extrapedicular approach. Preoperative planning determined targeted ablation zone and safety zones.
RESULTS: Mean baseline ODI of the treated cohort was 52±13, decreasing to a mean of 23±21 at 3 months follow-up (p<.001). The statistically significant improvement in ODI observed at 3 months was maintained through the 12-month follow-up. The mean baseline visual analogue scale score decreased from 61±22 to 45±35 at 3 months follow-up (p<.05), and the mean baseline physical component summary increased from 34.5±6.5 to 41.7±12.4 at 3 months follow-up (p=.03).
CONCLUSION: Ablation of the BVN for the treatment of chronic lumbar back pain significantly improves patients' self-reported outcome early in the follow-up period; the improvement persisted throughout the 1-year study period. Published by Elsevier Inc.

Entities:  

Keywords:  Back pain; Basivertebral nerve; Basivertebral nerve ablation; Electrocautery; Intraosseous nerves; Lumbar; Minimally invasive; Substance P

Mesh:

Year:  2016        PMID: 27592808     DOI: 10.1016/j.spinee.2016.08.032

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  15 in total

1.  Basivertebral foramina of true vertebrae: morphometry, topography and clinical considerations.

Authors:  Maria Tzika; George K Paraskevas; Maria Piagkou; Apostolos K Papatolios; Konstantinos Natsis
Journal:  Surg Radiol Anat       Date:  2021-02-17       Impact factor: 1.246

Review 2.  Decision Making: Osteoplasty, Ablation, or Combined Therapy for Spinal Metastases.

Authors:  William Lea; Sean Tutton
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513

3.  A prospective, open-label, single-arm, multi-center study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain.

Authors:  Eeric Truumees; Kevin Macadaeg; Enrique Pena; John Arbuckle; Jonathan Gentile; Robert Funk; Devender Singh; Sheetal Vinayek
Journal:  Eur Spine J       Date:  2019-05-21       Impact factor: 3.134

4.  Intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: a prospective randomized double-blind sham-controlled multi-center study.

Authors:  Jeffrey S Fischgrund; A Rhyne; J Franke; R Sasso; S Kitchel; H Bae; C Yeung; E Truumees; M Schaufele; P Yuan; P Vajkoczy; M DePalma; D G Anderson; L Thibodeau; B Meyer
Journal:  Eur Spine J       Date:  2018-02-08       Impact factor: 3.134

5.  International Society for the Advancement of Spine Surgery Guideline-Intraosseous Ablation of the Basivertebral Nerve for the Relief of Chronic Low Back Pain.

Authors:  Morgan Lorio; Olivier Clerk-Lamalice; Douglas P Beall; Terrence Julien
Journal:  Int J Spine Surg       Date:  2020-02-29

Review 6.  Basivertebral Nerve Ablation.

Authors:  Junjian Huang; Kevin Delijani; Jesse Jones; John Di Capua; Husamuddin El Khudari; Andrew J Gunn; Joshua Hirsch
Journal:  Semin Intervent Radiol       Date:  2022-06-30       Impact factor: 1.780

7.  Vertebrogenic Pain: A Paradigm Shift in Diagnosis and Treatment of Axial Low Back Pain.

Authors:  Aaron Conger; Matthew Smuck; Eeric Truumees; Jeffrey C Lotz; Michael J DePalma; Zachary L McCormick
Journal:  Pain Med       Date:  2022-07-20       Impact factor: 3.637

Review 8.  Basivertebral Nerve Ablation for the Treatment of Vertebrogenic Pain.

Authors:  Ivan Urits; Nazir Noor; Arjun Singh Johal; Joseph Leider; Joseph Brinkman; Nathan Fackler; Neeraj Vij; Daniel An; Elyse M Cornett; Alan D Kaye; Omar Viswanath
Journal:  Pain Ther       Date:  2020-10-31

Review 9.  Developments in Minimally Invasive Surgical Options for Vertebral Pain: Basivertebral Nerve Ablation - A Narrative Review.

Authors:  Vinicius Tieppo Francio; David Sherwood; Eric Twohey; Brandon Barndt; Robert Pagan-Rosado; James Eubanks; Dawood Sayed
Journal:  J Pain Res       Date:  2021-06-23       Impact factor: 3.133

10.  Transforaminal Epiduroscopic Basivertebral Nerve Laser Ablation for Chronic Low Back Pain Associated with Modic Changes: A Preliminary Open-Label Study.

Authors:  Hyeun Sung Kim; Nitin Adsul; Farid Yudoyono; Byapak Paudel; Ki Joon Kim; Sung Ho Choi; Jeong Hoon Kim; Sung Kyun Chung; Jeong-Hoon Choi; Jee-Soo Jang; Il-Tae Jang; Seong-Hoon Oh
Journal:  Pain Res Manag       Date:  2018-08-14       Impact factor: 3.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.